Trial Profile
A Study to Evaluate Whether Natalizumab Modifies the Changes in Melatonin and Oxidative Stress Biomarkers in Patients With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 22 Feb 2016 New trial record